

1. Bell DW. Our changing view of the genomic landscape of cancer. *J Pathol* 2010;2:231–243.
2. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. *Science* 2007;318:1108–1113.
3. Velculescu VE. Defining the blueprint of the cancer genome. *Carcinogenesis* 2008;29:1087–1091.
4. Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and future. *Annu Rev Genomics Hum Genet* 2008;9:321–345.
5. Foulkes WD. Inherited susceptibility to common cancers. *N Engl J Med* 2008;359:2143–2153.
6. Hirschfeld KM, Rebbeck TR, Levine AJ. Germline mutations and polymorphisms in the origins of cancers in women. *J Oncol* 2010;2010:297671.
7. Narod SA. Modifiers of risk of hereditary breast cancer. *Oncogene* 2006;25:5832–5836.
8. Chenevix-Trench G, Milne RL, Antoniou AC, et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Res* 2007;9:104.
9. Antoniou AC, Sinilnikova OM, McCuffog L, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet* 2009;18:4442–4456.
10. Antoniou AC, Spurdle AB, Sinilnikova OM, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Am J Hum Genet* 2008;82:937–948.
11. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst* 2013;105:812–822.
12. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. *Oncogene* 2006;25:5846–5853.
13. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. *Cell* 2002;2:171–182.
14. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361:123–134.
15. Iglehart JD, Silver DP. Synthetic lethality—a new direction in cancer-drug development. *N Engl J Med* 2009;2:189–191.
16. Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. *Clin Cancer Res* 2012;18:510–523.
17. Ma W, Halweg CJ, Menendez D, et al. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. *Proc Natl Acad Sci U S A* 2012;109:6590–6595.
18. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. *Cancer Res* 2012;72:5588–5599.
19. Patel AG, De Lorenzo SB, Flatten KS, et al. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. *Clin Cancer Res* 2012;18:1655–1662.
20. Shen Y, Rehman FL, Feng Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. *Clin Cancer Res* 2013;19:5003–5015.
21. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. *Nature* 2008;451:1111–1115.
22. Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. *J Clin Oncol* 2011;29:3008–3015.
23. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature* 2008;451:1116–1120.
24. Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. *Nat Struct Mol Biol* 2010;17:688–695.
25. Jaspers JE, Kersbergen A, Boon U, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. *Cancer Discov* 2013;3:68–81.
26. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. *Nat Genet* 2008;40:17–22.
27. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. *J Clin Oncol* 2012;30:958–964.
28. Win AK, Lindor NM, Jenkins MA. Risk of breast cancer in Lynch syndrome: a systematic review. *Breast Cancer Res* 2013;15:R27.
29. Xu Q, He CY, Liu JW, et al. Pre-miR-27a rs895819A/G polymorphisms in cancer: a meta-analysis. *PLoS One* 2013;8:e65208.
30. Hoffman AE, Zheng T, Yi C, et al. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. *Cancer Res* 2009;69:5970–5977.
31. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). *Curr Protoc Hum Genet* 2008;Chapter 10: Unit 10.11.
32. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. *Nature* 2009;458:719–724.
33. Copeland NG, Jenkins NA. Deciphering the genetic landscape of cancer—from genes to pathways. *Trends Genet* 2009;25:455–462.
34. Kao J, Pollack JR. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. *Genes Chromosomes Cancer* 2006;45:761–769.
35. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. *Cancer Cell* 2006;10:529–541.
36. Bentires-Alj M, Gil SC, Chan R, et al. A role for the scaffolding adapter GAB2 in breast cancer. *Nat Med* 2006;12:114–121.
37. Yu Q, Sicinska E, Geng Y, et al. Requirement for CDK4 kinase function in breast cancer. *Cancer Cell* 2006;9:23–32.
38. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. *Nature* 2000;406:747–752.
39. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001;98:10869–10874.
40. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature* 2012;490:61–70.
41. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 2012;486:346–352.
42. Perou CM. Molecular stratification of triple-negative breast cancers. *Oncologist* 2010;15:39–48.
43. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest* 2011;121:2750–2767.
44. Gruberger S, Ringnér M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. *Cancer Res* 2001;61:5979–5984.
45. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 2002;415:530–536.
46. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol* 2013;24:2206–2223.
47. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med* 2002;25:1999–2009.
48. Piccart M, Loi S, Van't Veer L, et al. Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: Are the results still outperforming the clinical-pathological criteria? Presented at: 2004 27th San Antonio Breast Cancer Symposium; December 2004; San Antonio, TX.
49. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. *J Clin Oncol* 2003;21:3357–3365.
50. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. *J Natl Cancer Inst* 2006;98:262–272.
51. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. *N Engl J Med* 2004;351:2817–2826.
52. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol* 2010;11:55–65.
53. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. *J Clin Oncol* 2010;10:1677–1683.
54. Tang G, Cuzick J, Costantino JP, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. *J Clin Oncol* 2011;29:4365–4372.
55. Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. *J Clin Oncol* 2003;21:4611–4619.
56. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. *Cancer Cell* 2004;5:607–616.
57. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with estrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. *Lancet Oncol* 2013;14:1067–1076.
58. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. *J Clin Oncol* 2004;22:2284–2293.
59. Acharya CR, Hsu DS, Anders CK, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. *JAMA* 2008;299:1574–1587.
60. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J Clin Oncol* 2007;33:5287–5312.
61. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. *Cell* 2007;129:823–837.

62. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. *J Mammary Gland Biol Neoplasia* 2010;15:5–17.
63. Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor- α levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. *Clin Cancer Res* 2007;13:4882–4890.
64. Zhou Q, Shaw PG, Davidson NE. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. *Breast Cancer Res Treat* 2009;117:443–451.
65. Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. *Clin Oncol* 2013;31:2128–2135.
66. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. *Nature* 2003;425:415–419.
67. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* 2000;403:901–906.
68. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. *Clin Cancer Res* 2008;5:1340–1348.
69. Foekens JA, Sieuwerts AM, Smid M, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. *Proc Natl Acad Sci U S A* 2008;105:13021–13026.
70. Iorio MV, Casalini P, Tagliabue E, et al. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. *Eur J Cancer* 2008;18:2753–2759.
71. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. *Mol Cancer Ther* 2008;7:2152–2159.
72. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. *J Biol Chem* 2008;283:29897–29903.
73. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57–70.
74. Oesterreich S, Davidson NE. The search for ESR1 mutations in breast cancer. *Nature Genet* 2013;45:1415–1416.
75. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. *Clin Cancer Res* 2007;13:1950–1954.
76. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* 2013;9869:805–816.
77. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012;366:520–529.
78. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol* 2001;2:127–137.
79. Hudis CA. Trastuzumab—mechanism of action and use in clinical practice. *N Engl J Med* 2007;1:39–51.
80. Jhaveri K, Esteva FJ. Pertuzumab in the treatment of HER2+ breast cancer. *J Natl Compr Canc Netw* 2014;12:591–598.
81. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. *Nat Rev Cancer* 2008;8:579–591.
82. Hynes NE, Dey JH. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. *Cancer Cell* 2009;5:353–355.